Lack of efficacy of hydroxychloroquine in covid-19
<p>Studies in mild-to-moderate cases as well as severe disease leave us still searching for a magic pill. (Editorial)
Drugs
-
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
<p>The objective of the study was to assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).</p>
-
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data
<p>The objective of the study wast to assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen.</p>
-
Flooded by the torrent: the COVID-19 drug pipeline
<p>The coronavirus disease 2019 (COVID-19) drug pipeline is not growing at quite the same speed as the pandemic. But its rate of expansion is nevertheless cause for pause. In the months since COVID-19
-
A trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19
<p>Researchers conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen
-
Coronavirus ourbreak: ICMR gets nod for ‘restricted use’ of two anti-HIV drugs
The Indian Council of Medical Research (ICMR) has obtained permission for “restricted use in public health emergency” of two second-line HIV medications for use against the novel coronavirus (nCoV).
-
Predicting and designing therapeutics against the Nipah virus
<p>Despite Nipah virus outbreaks having high mortality rates (>70% in Southeast Asia), there are no licensed drugs against it. In this study, we have considered all 9 Nipah proteins as potential <a
-
Question raised in Lok Sabha on Drug Resistant TB Cases, 06/12/2019
Question raised in Lok Sabha on Drug Resistant TB Cases, 06/12/2019. India has the largest number of individuals suffering from drug resistant TB. However, as per the latest global TB report, India ranks
-
Outpatient antibiotic prescription rate and pattern in the private sector in India: Evidence from medical audit data
<p>The key objective of this research was to generate new evidence on outpatient antibiotic prescription rate and patterns in the private sector in India. We used 12-month period (May 2013 to April 2014)
-
Addressing poverty in India’s Revised National Tuberculosis Control Programme: are we failing to harness the opportunities?
<p>The bi-directional relationship between poverty and tuberculosis (TB) is well established. Poverty aggravates material disadvantage, social exclusion, discrimination in participation across a wide range